Unfortunately, the Food and Drug Administration rejected approval of the pharmaceutical Flibanserin, which is designed to treat the decreased sexual desire of women. Flibanserin, sometimes known as either Girosa or ‘female Viagra’ was rejected 10 votes to 1 by an FDA Advisory Panel who claimed that the submitted data from the clinical trials had no considerably better effect than a placebo. As seen in this article we published, “Women who were under the effects of Flibanserin claimed to have had sexually satisfying events more often than before using the drug. In fact, a raise from 2.8 to 4.5 times a month was shown by the results.”

Paula Hillard, a gynecologist at the Stanford University School of Medicine is not convinced of the clinical meaningful benefit of Flibanserin. We, on the other hand, are quite assured of the positive benefits of Flibanserin, and believe that the FDA will eventually reconsider their decision. We believe Flibanserin will have the biggest impact on pre-menopausal women with Hypoactive Sexual Desire Disorder.

Flibanserin was elaborated by the German Company Boehringer Ingelheim and was promoted as a product capable of providing “satisfying sexual events” for pre-menopausal women with ‘Hypoactive Sexual Desire Disorder’ known as HSDD. Many individuals claim that HSDD does not exist, and that women may not suffer from any sort of sexual dysfunction, but instead that it is all in their heads. Therefore, the introduction of Flibanserin has sparked a lot of controversy in the pharmaceutical industry. Currently, Flibanserin / Girosa are not approved for sale in any country, but everyone is working hard to change this. Please stay tuned for additional updates and information.